• Akira Shirahata, Jun Mimuro, Hoyu Takahashi, Isao Kitajima, Hajime Tsuji, Yutaka Eguchi, Tadashi Matsushita, Masahiro Kajiki, Goichi Honda, and Yoichi Sakata.
• University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, a-shirahata@kitakyu-hp.or.jp.
• Eur. J. Pediatr. 2014 Mar 1;173(3):303-11.

UnlabelledRecombinant soluble human thrombomodulin (TM-α) has been shown to be useful in the treatment of disseminated intravascular coagulation (DIC) in a heparin-controlled study and has been available for clinical use in Japan since 2008. However, data on its use for neonatal DIC have not been reported from any clinical studies, so efficacy and safety were analyzed in 60 neonatal DIC patients identified in post-marketing surveillance. The DIC resolution rate as of the day after last administration of TM-α was 47.1 %, and the survival rate at 28 days after last administration was 76.7 %. Hemostatic test result profiles revealed decreased levels of fibrin/fibrinogen degradation products and increased platelet counts and antithrombin activity. Incidences of adverse drug reactions, bleeding-related adverse drug reactions, and bleeding-related adverse events were 6.7, 6.7, and 16.7 %, respectively, with no significant differences between neonatal, pediatric (excluding neonates), and adult DIC patients.ConclusionThis surveillance provided real-world data on the safety and effectiveness of TM-alpha in the treatment of neonatal DIC in general practice settings.

13 keywords...

hide…